1. Office for National Statistics. Overview of the UK Population: November 2018. 2018.
2. Gao L, Maidment I, Matthews FE, Robinson L, Brayne C. Medication usage change in older people (65+) in England over 20 years: Findings from CFAS I and CFAS II. Age Ageing 2018; 47.
3. Arthur A, Savva G, Barnes L et al. Changing prevalence and treatment of depression among the over-65s over two decades: findings from the Cognitive Function and Ageing Studies. Br J Psychiatry 2019; 1–6.
4. Campbell N, Boustani M, Limbil T et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009; 4: 225–233.
5. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: A review and practical application. Aging health 2008; 4.
6. Puhan MA, Bachmann LM, Kleijnen J, ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: A network meta-analysis. BMC Med 2009; 7: 1–14.
7. Fox C, Richardson K, Maidment ID et al. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011; 59: 1477–1483.
8. Richardson K, Bennett K, Maidment ID, Fox C, Smithard D, Kenny RA. Use of Medications with Anticholinergic Activity and Self-Reported Injurious Falls in Older Community-Dwelling Adults. J Am Geriatr Soc 2015; 63: 1561–1569.
9. Kim SJ, Jung D, Shim JC et al. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. Asian J Psychiatr 2019; 46: 111–117.
10. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic Drug Exposure and the Risk of Dementia. JAMA Intern Med 2019; 1–10.
11. Gray SL, Anderson ML, Dublin S et al. Cumulative Use of Strong Anticholinergics and Incident Dementia. JAMA Intern Med 2015; 175: 401.
12. Richardson K, Fox C, Maidment I et al. Anticholinergic drugs and risk of dementia : case-control study. BMJ 2018: 1–12.
13. Gray SL, Hanlon JT. Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf 2016; 2042098616658399.
14. Fox C, Smith T, Maidment I et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014; 43: 604–615.
15. Kachru N, Carnahan RM, Johnson ML, Aparasu RR. Potentially Inappropriate Anticholinergic Medication Use in Community-Dwelling Older Adults: A National Cross-Sectional Study. Drugs and Aging 2015; 32: 379–389.
16. Sumukadas D, McMurdo MET, Mangoni AA, Guthrie B. Temporal trends in anticholinergic medication prescription in older people: Repeated crosssectional analysis of population prescribing data. Age Ageing 2014; 43: 515–521.
17. Rhee TG, Choi YC, Ouellet GM, Ross JS. National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults. J Am Geriatr Soc 2018; 66: 1382–1387.
18. Matthews FE, Arthur A, Barnes LE et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: Results of the cognitive function and ageing study i and II. Lancet 2013; 382: 1405–1412.
19. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.
20. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. Psychol Med 1998; 28: 319–335.
21. National Institute for Health and Care Excellence. Dementia: Assessment, management and support for people living with dementia and their carers. NICE 2018 540–540 https://www.nice.org.uk/guidance/ng97/resources/dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109 (25 June 2019, date last accessed).
22. Forde JC, Chughtai B, Cea M, Stone B V, Te A, Bishop TF. Trends in Ambulatory Management of Urinary Incontinence in Women in the United States. Female Pelvic Med Reconstr Surg 2017; 23.
23. Margulis A V., Linder M, Arana A et al. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One 2018; 13: 1–13.
24. Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995 – 2007 : Br J Gen Pr 2011; 565–572.
25. Leth-møller KB, Hansen AH, Torstensson M et al. Antidepressants and the risk of hyponatremia : a Danish register-based population study. 2016; 1–8.
26. Daniel S, Amir S, Bronislava C, Talia D-C, Benaya R-Z, Anat G-G. Medication Induced SIADH: Distribution and Characterization According to Medication Class. Br J Clin Pharmacol 2017;
27. Goodarzi ZS, Mele BS, Roberts DJ, Holroyd-Leduc J. Depression Case Finding in Individuals with Dementia: A Systematic Review and Meta-Analysis. J Am Geriatr Soc 2017;
28. Aston L, Hilton A, Moutela T, Shaw R, Maidment I. Exploring the evidence base for how people with dementia and their informal carers manage their medication in the community: A mixed studies review. BMC Geriatr 2017; 17.
29. Maidment ID, Haw C, Stubbs J, Fox C, Katona C, Franklin BD. Medication errors in older people with mental health problems: a review. Int J Geriatr Psychiatry 2008; 23: 564–573.
30. Foster ER. Instrumental activities of daily living performance among people with parkinson’s disease without dementia. Am J Occup Ther 2014; 68: 353–362.
31. Maidment ID, Aston L, Moutela T, Fox CG, Hilton A. A qualitative study exploring medication management in people with dementia living in the community and the potential role of the community pharmacist. Heal Expect 2017; 20: 929–40.
32. Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open 2013; 3: e002080.
33. Balinskaite V. Trends and geographical variation in antidepressant prescribing in primary care in England: a descriptive analysis. Lancet 2019; 394: S21.
34. Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews. Drugs and Aging 2018; 35: 523–538.
35. Maidment I, Booth A, Mullan J, McKeown J, Bailey S, Wong G. Developing a framework for a novel multi-disciplinary, multi-agency intervention(s), to improve medication management in community-dwelling older people on complex medication regimens (MEMORABLE)--a realist synthesis. Syst Rev 2017; 6.